Conduit Pharmaceuticals Inc. has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products of its autoimmune pipeline for use in future clinical trials. Conduit has developed a series of novel, advantageous solid forms of all its autoimmune pipeline assets, each protected by newly established composition-of-matter intellectual property (IP). Leveraging Agility’s extensive formulation expertise, this colla...